Infinity Pharmaceuticals | INFI - Beneficio Bruto En Ventas





Beneficio Bruto En Ventas Cambio Fecha
AbbVie USD 10.47B 605M 2025-09
Amgen USD 6.48B 307M 2025-09
AstraZeneca USD 12.39B 5M 2025-12
Bristol-Myers Squibb USD 8.79B 110M 2025-09
Cipla INR 41.64B 6.31B 2025-12
Clal Biotechnology ILS -857K 1.42M 2022-06
Compugen USD 241K 649K 2025-09
CSL USD 4.46B 2.71B 2025-12
Eisai JPY 168.85B 17.02B 2025-12
Eli Lilly USD 14.59B 1.48B 2025-09
Gilead Sciences USD 6.31B 106M 2025-12
GlaxoSmithKline GBP 6.18B 106M 2025-12
Grifols EUR 766.49M 39.74M 2024-12
Incyte USD 1.39B 118.68M 2025-12
Infinity Pharmaceuticals USD 231K 59K 2023-06
Ionis Pharmaceuticals USD 195M 40M 2025-12
J&J USD 16.6B 118M 2025-12
Novartis USD 10.82B 695M 2025-09
Pfizer USD 3.54B 7.61B 2025-09
Roche Holding CHF 22.09B 10.04B 2025-12
TG Therapeutics USD 154.43M 20.81M 2025-12